Mentor's synthetic pelvic prolapse mesh:
This article was originally published in Clinica
Executive Summary
Mentor has received US FDA 510(k) clearance to sell its first synthetic mesh product for treating pelvic organ prolapse, NovaSilk. The use of synthetic meshes for the treatment of pelvic organ prolapse represents one of the fastest growing segments of the women's health market, claimed the Santa Barbara, California firm, which already sells two human tissue-based products for the condition. NovaSilk comprises a macroporous, knitted, monofilament polypropylene mesh, while also being soft and light. It offers resistance to traction, allows tissue colonisation and facilitates positioning during surgery, the company said. According to Mentor, pelvic organ prolapse is estimated to afflict around 36 million women in the US and Europe.
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.